BOCOM International Holdings Company Sticks to Its Buy Rating for Simcere Pharmaceutical Group Limited (2096)Tip Ranks·1 day ago, 03:45 AM02096-0.78%
Huatai Securities Sticks to Their Buy Rating for Simcere Pharmaceutical Group Limited (2096)Tip Ranks·Aug 24 at 12:15 AM02096-0.78%
Simcere Pharmaceutical grants 795,000 RSUs under 2021 share award schemePUBT·Aug 21 at 05:45 AM02096-0.78%
Simcere Pharmaceutical Delivers Double-Digit Growth on Innovative Drug MomentumTip Ranks·Aug 20 at 10:08 AM02096-0.78%
Simcere Launches RMB1 Billion Share Buyback to Signal Confidence in OutlookTip Ranks·Aug 20 at 10:08 AM02096-0.78%
Simcere Pharmaceutical files board, committee member list with disclosure responsibilitiesPUBT·Aug 20 at 09:55 AM02096-0.78%
Simcere Pharmaceutical launches open-market share buyback of up to RMB 1 billionPUBT·Aug 20 at 09:53 AM02096-0.78%
Simcere Pharmaceutical climbs 4% on Moderna-Merck vaccine trial boostHK Stock Market Update·Aug 19 at 08:44 PM02096-0.78%
Biotech Spinoffs and Boardroom Shakeups Drive Hong Kong’s Mid-Cap FringesGlobal Report·Aug 18 at 04:43 AM01167+8.61%02680-1.45%
Simcere Pharma sets board meeting to review interim results, consider dividendPUBT·Aug 10 at 05:59 AM02096-0.78%
Simcere Pharmaceutical Group Limited (2096) Receives a Buy from UBSTip Ranks·Jul 27 at 07:27 PM02096-0.78%
HKEX Sector Rotation: Mobility, Biotech, and Consumer Staples Navigate Strategic Shifts in 2026Global Report·Jul 21 at 04:13 AM02643+0.57%01780+1.69%
